Clinical Trial

CALLY Index and Disease Activity in Ankylosing Spondylitis

Completed
View on ClinicalTrials.gov →
Summary
This retrospective cross-sectional observational study aims to evaluate the association between the C-reactive protein-albumin-lymphocyte (CALLY) index and disease activity and functional status in patients with ankylosing spondylitis. Medical records of adult patients followed between January 1, 2022, and December 31, 2025, were reviewed. Disease activity was assessed using BASDAI and ASDAS-ESR, and functional status was evaluated using BASFI. The study investigates whether the CALLY index reflects systemic inflammatory burden beyond patient-reported disease activity
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-29.
Trial Details
NCT Number NCT07509463
Lead Sponsor Bursa City Hospital
Conditions Anklyosing Spondylitis
Enrollment 65 participants
Start Date 2022-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-08